[제약사 리포트] 유한양행, 1Q 렉라자 수익 '기대 이하' 왜?

Yuhan Corporation's lower-than-expected Q1 license revenue highlights how accounting adjustments in co-development contracts can temporarily obscure the strong global sales performance of its key drug, Leclaza. This gap underscores the importance of upcoming milestone payments from European launches as a more accurate gauge of the company's long-term profitability and its partnership synergy with Johnson & Johnson.